• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6848.TWO
Share

RBC Bioscience Corporation Stocks

NT$ 20.75Last Updated 20.10.2026

Issuer Rating

4/7
Performance

Strong

Risk

High

Recommendation

Hold

Market Cap

NT$ 9.18M

NT$ 20.75
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

RBC Bioscience Corporation is a firm dedicated to the research, development, production, and sale of specialized reagents and advanced equipment. These products cater to the life sciences and molecular diagnostic sectors. Its market reach is extensive, covering Europe, the United States, Asia, Taiwan, Africa, and Australia. The company's diverse product line includes reagents tailored for molecular biomedical diagnostics and scientific research, alongside automated instruments for gene and nucleic acid extraction. It also provides a range of nucleic acid extraction kits and associated reagent tissues. Sales are primarily conducted through a global network of distributors. Established in 1995, RBC Bioscience Corporation maintains its headquarters in New Taipei City, Taiwan.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

20.10.2026 21:47

"A Roller-Coaster Ride for Stocks": What Wall Street Is Saying Ahead of SpaceX's Earnings Report

20.10.2026 20:36

Why Cathie Wood's team expects Tesla's stock to rise by more than 1,000%

20.10.2026 20:11

"A Vicious Cycle": What Risks Does Rising Bond Yields Pose to the Stock Market?

20.10.2026 19:39

"The Weak Link": The risk premium on French government bonds has approached a 15-year high

20.10.2026 19:05

Veradermics jumps on successful hair-loss pill trial. Is the stock a buy?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026